This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page | Contact Us | Sign In | Join
News & Press: Advocacy and Policy

Tell Congress to Pass Nursing Workforce Programs and the Lymphedema Treatment Act

Tuesday, December 4, 2018   (0 Comments)
Posted by: Becky Carroll
Share |
Congress will adjourn the 115th session at the end of December and two WOCN Society priority issues are still pending: passage of the Lymphedema Treatment Act and passage of Title VIII Nursing Workforce Reauthorization Act. We need your help to encourage Congress to get these priorities done, or they will have to be reintroduced next session.

First, as the 115th Congress enters its final stretch, we are learning that a last minute provision to include for-profit facilities in the Title VIII Loan Repayment Program could put the passage of the entire Title VIII Nursing Workforce Reauthorization Act in jeopardy. The Title VIII NURSE Corps Loan Repayment Program, one of the Title VIII Nursing Workforce Development Programs, was created to assist those nurses who are willing to work in the areas with critical staffing needs and depressed salaries. Already oversubscribed, adding a provision to allow for-profit facilities as eligible entities to this program needs to be thoroughly vetted, and questions must be answered to avoid any unintentional consequences that could adversely impact those who rely on this loan repayment and the communities they serve.

Let your Senators know how essential these Title VIII Nursing Workforce programs are to you, to the nursing profession, to our patients and to our communities. If you have been a recipient of the Title VIII Loan Repayment Program, or any Title VIII Program, let your Senator know by sending a message via email or by postal mail. For your convenience, we have prepared a pre-written message regarding Title VIII. Your voice is vital to ensuring these nursing workforce programs are reauthorized this year.

Secondly, time is growing short for Congress to pass the Lymphedema Treatment Act. Thanks in part to the support of WOCN members, the Lymphedema Treatment Act (H.R. 930/S.497) is now the most supported healthcare bill currently before Congress. This is a tremendous achievement, but it is meaningless if Congress doesn’t pass the bill--and time is running out! We can still do more to ensure that Congress passes this important legislation.  Please contact your members of Congress by clicking the button below and ask that they pass the Lymphedema Treatment Act (H.R. 930/S.497) as soon as possible!
If you have questions, please contact:
Chris Rorick, MPH
Director of Government Relations
+1 202-508-6354
Kate Lawrence, MSN, RN, CWOCN
WOCN Public Policy Coordinator

Join Now Contact Us: 888-224-WOCN(9626) Advertising

Copyright 2018 Wound, Ostomy and Continence Nurses Society™. All rights reserved.

The WOCN® Society is professionally managed by Association Headquarters, a charter accredited association management company.

The Wound, Ostomy and Continence Nurses Society is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The Wound, Ostomy and Continence Nurses Society is approved by the California Board of Registered Nursing, Provider Number CEP 15115.

The WOCN® Society does not endorse or support products or services.

PLEASE BE ADVISED: The names and contact information for all individuals listed on this site is privileged, confidential information and intended for specific purposes. No one (individual or company) may use any contact information on the WOCN Society website to contact, to distribute information to, or solicit anyone for any reason other than the intended purpose for which the name and contact information is available. Click here to view our detailed Privacy Policy.